H3N2 VLP 

H3N2 virus-like particles (VLPs) are engineered, non-infectious particles that mimic the structural and antigenic properties of the influenza A H3N2 virus. These VLPs lack viral genetic material, making them safe for use in vaccine development, immunological research, and therapeutic applications.

Structure of H3N2 VLPs

H3N2 VLPs consist of critical viral proteins that self-assemble to form particles resembling the native virus. Key components include:

  • Hemagglutinin (HA): The primary antigen responsible for binding to host cells, crucial for vaccine efficacy.
  • Neuraminidase (NA): Plays a role in viral release from host cells and is an important secondary target for immune responses.
  • Matrix Proteins (M1, M2): Provide structural support and drive VLP assembly.
Production Systems

H3N2 VLPs are commonly produced in various host systems, including:

  • Insect Cells (e.g., using baculovirus expression): Ensures proper folding and high production yield.
  • Mammalian Cells: Enables post-translational modifications closely resembling human influenza viruses.
  • Yeast Systems: Offers cost-effective production with scalable options.
Applications
  • Vaccines
    • Prophylactic Vaccines: H3N2 VLP-based vaccines elicit strong immune responses, particularly against the HA and NA antigens, providing protection against seasonal and pandemic strains.
    • Rapid Response Vaccines: The rapid production capabilities of VLPs make them ideal for addressing H3N2 outbreaks.
  • Immunological Studies
    • H3N2 VLPs are used to study host immune responses, particularly the generation of neutralizing antibodies and T-cell activation against HA and NA.
  • Diagnostics
    • H3N2 VLPs serve as antigens in serological assays for detecting influenza-specific antibodies.

H3N2 virus-like particles are a cutting-edge solution for combating influenza, offering rapid production, safety, and strong immunogenicity. Continued research and advancements in VLP technology aim to optimize their efficacy, reduce production costs, and enhance their use in global influenza prevention strategies.

For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD